Figure 1. Enrollment and outcomes

Slides:

Advertisements

Similar presentations

Volume 24, Issue 5, Pages (May 2016)

Advertisements

Figure 1 Patient selection flow chart

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Mechanism of mortality benefit associated with radial access

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 5 The effect of the spider color morph encountered by honeybees in Experiment 2 on the proportion of honeybees ... Figure 5 The effect of the spider.

FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome.

Table 4. Comparison of screening guidelines in terms of the total number and percentages of patients screened for ... Table 4. Comparison of screening.

FIGURE 3 Incidence of anemia by WDDS category at baseline and endpoint

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1. Clinical course, treatment and titres of anti-ssDNA antibodies

Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.

Source: Figure created by the author based on data ...

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

Fig. 1 Mean change from baseline in ANC ± s. e

(A) The 10 most commonly involved organs in female and male ...

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Figure 1 Mean ± standard error proportions of (a) courtship and (b) copulation by female-male type pairing. Error bars ... Figure 1 Mean ± standard error.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1. CONSORT flow diagram

FIGURE 1 Study consort diagram

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

Figure 1. The derivation of the cohort.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Figure 1. Results of search based on the PRISMA statement.14

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

FIGURE 1 Major activities in the working week of a banker

Figure 1 Patient disposition

Figure 1. Randomization and dropouts.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Weight loss for participants (n = 128) who consumed the high-egg (n = 66) or the low-egg (n = 62) diets ... FIGURE 1 Weight loss for participants.

FIGURE 1 Study population. EVD, Ebola virus disease.

Fig. 1 A network representation of top 100 co-occurring terms

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Patient selection.

The figure shows the fraction of ...

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1: World distribution of field sampling locations of Aedes aegypti and Aedes mascarensis screened for Wolbachia ... Fig. 1: World distribution of.

Enrollment, outcomes, and pharmacokinetics.

FIGURE 1 Study and analyses workflow

Figure 1 Percentage of male and female helpers in different categories

Figure 1 Mechanisms of mitral regurgitation.

Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < vs ... Figure 1. Mean change in BW (kg)

Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic ... Figure 1. Adjusted survival curves.

Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1. Parenting Evaluations by Parenting Style, Education, and Vignette Parent Gender. Unless provided in the caption above, the following copyright.

Figure 1. Consolidated Standards of Reporting Trials (or CONSORT) diagram for the current study. Unless provided in the caption above, the following copyright.

Figure 1. Measuring respondent unhappiness with their child marrying someone from the other party and happiness with ... Figure 1. Measuring respondent.

Figure 1 ABCDE of primary prevention.2

Figure 1. (A) Composite renal outcome, (B) worsening kidney function, and (C) incident albuminuria by fasting glucose ... Figure 1. (A) Composite renal.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Evolutionary process of a policy field.

Figure 1. Kaplan–Meier curves showing the impact of the different pretreatment HIV-1 drug resistance categories on the ... Figure 1. Kaplan–Meier curves.

Presentation transcript:

Figure 1. Enrollment and outcomes Figure 1. Enrollment and outcomes. A total of 279 male patients with metabolic syndrome were recruited either in the ... Figure 1. Enrollment and outcomes. A total of 279 male patients with metabolic syndrome were recruited either in the outpatient clinics of the two participating centers or through newspaper advertisements. Of those, 81 patients did not respond, were not interested, or were not eligible on the basis of their medical history. Of the 198 patients who underwent physical and biochemical screening, 128 were found to be ineligible according to entry criteria, in most cases because they had either a total testosterone level of >12 nmol/L or a BMI <30 kg/m<sup>2</sup>. Seventy patients were randomly assigned to receive either anakinra or placebo. In the anakinra group, one patient was excluded due to regular cannabis abuse that he concealed from the investigators at screening and one patient withdrew after 3 d of treatment due to extensive lipodystrophy from long-standing insulin treatment. In the placebo group one patient was excluded due to lower respiratory tract infection at day 1 with a CRP level of 49.2 mg/L. A total of 67 patients completed the 4-wk treatment and evaluation of study endpoints. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2018 Endocrine Society None, Volume 103, Issue 9, 22 June 2018, Pages 3466–3476, https://doi.org/10.1210/jc.2018-00739 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2. Changes in total testosterone levels during the 4-wk study period. (A) Average absolute differences in total ... Figure 2. Changes in total testosterone levels during the 4-wk study period. (A) Average absolute differences in total testosterone levels between the baseline value and measurements at days 1, 7, and 28 during the 4-wk study period. (B) Average absolute difference in total testosterone levels at 4 wk in each study group stratified by on-treatment CRP reduction at 1 wk. (C) Average absolute difference in total testosterone levels at 4 wk in each study group stratified by baseline values of CRP. (D) Average absolute difference in total testosterone levels at 4 wK in each study group stratified by baseline BMI. The error bars indicate SE. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2018 Endocrine Society None, Volume 103, Issue 9, 22 June 2018, Pages 3466–3476, https://doi.org/10.1210/jc.2018-00739 The content of this slide may be subject to copyright: please see the slide notes for details.